Stanford scientists have developed a working model that chemotherapy drugs induce peripheral neuropathy by activating a pathway that favors neuronal degeneration and impairs sensory neuron function.
Brief Description: Inventors at Stanford have developed a novel fiber-optic technology to achieve unprecedented sensitivity and immunity to motion artifacts that can be used in freely moving animals.
Inventors at Stanford have developed a novel strategy to perform concurrent fluorescence measurements of multiple biological parameters in freely moving and head-restrained animals.
Stanford scientists have discovered multiple functionally biased ligands that can selectively activate distinct subsets of signaling pathways downstream of the complement 5a receptor.
Researchers at Stanford have found that applying pressure to macroencapsulation can enhance insulin transport from encapsulated islet beta cells to surrounding tissue and assist in glucose metabolism in type 1 diabetes (T1D) patients.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Stanford scientists have discovered that blocking an immune receptor signal can lead to increased fat uptake and weight reduction in patients suffering from obesity and associated diseases.
Stanford researchers have developed an innovative approach for accurate and automated cell classification on H&E-stained images using multiplexed immunofluorescence (mIF) imaging, eliminating human annotations, and enhancing biological interpretability in histopathology.
A new deep-learning system called Atomic Rotationally Equivariant Scorer (ARES) significantly improves the prediction of RNA structures over previous artificial intelligence (AI) models.
Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.
Stanford researchers have developed a pioneering gene therapy by targeting reactive astrocytes in the optic nerve head (ONH) and modulating cyclic adenosine monophosphate (cAMP) levels for targeted treatment of glaucoma and other retinal disorders.